iShares U.S. Healthcare ETF IYH
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +19.20%
- 1 year
- +27.51%
- Open
- 77.63
- Prev close
- 77.81
- Mkt cap
- 4.64B
- Vol
- 1.47M
- Avg vol
- 827.54K
- EPS
- 2.39
- P/E
- 32.53
- Div yield
- 0.00%
More statistics
- Low
- 77.13
- High
- 77.95
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 72.73
- 200-d avg
- 66.76
- 1y target
- 0.00
5D chart
Signals (104)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 10:25 AM | 17 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 17 hours ago |
| RSI: Oversold | Nov 2, 9:40 AM | 17 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 9:30 AM | 17 hours ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 3 days ago |
Newest 20 of 104.
News
15 hours ago benzinga.com
Kalshi, Polymarket Put Democrats' Senate Odds At More Than 70%: 5 ETFs That Could Move If They're Wrong
Kalshi and Polymarket give Democrats 73.5% Senate odds. Here are five ETFs that could react if the predictions miss.
6 days ago defenseworld.net
Citizens Financial Group Inc. RI Acquires New Holdings in iShares U.S. Healthcare ETF $IYH
Citizens Financial Group Inc. RI bought a new position in iShares U.S. Healthcare ETF (NYSEARCA:IYH) in the third quarter, according to the company in its most recent filing with the SEC. The fund…
1 week ago zacks.com
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
Launched on June 12, 2000, the iShares U.S. Healthcare ETF (IYH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity…
1 week ago fool.com
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF
Vanguard Health Care ETF provides significantly broader exposure with 411 holdings compared to 100 for iShares U.S. Healthcare ETF. The Vanguard fund maintains a lower expense ratio of 0.09%, while…
2 weeks ago defenseworld.net
iShares U.S. Healthcare ETF (NYSEARCA:IYH) Sees Unusually-High Trading Volume – Should You Buy?
Shares of iShares U.S. Healthcare ETF (NYSEARCA:IYH - Get Free Report) saw unusually-high trading volume on Friday. Approximately 614,797 shares changed hands during mid-day trading, a decline of 22%…
2 weeks ago defenseworld.net
First Citizens Bank & Trust Co. Buys 9,175 Shares of iShares U.S. Healthcare ETF $IYH
First Citizens Bank and Trust Co. purchased a new stake in iShares U.S. Healthcare ETF (NYSEARCA:IYH) during the third quarter, according to its most recent 13F filing with the Securities and…
3 weeks ago fool.com
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
The iShares U.S. Healthcare ETF offers a lower expense ratio and a higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides concentrated exposure to over 200…
3 weeks ago fool.com
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield
iShares Global Healthcare ETF provides broad exposure to international medical companies with a higher dividend yield than its domestic counterpart. iShares U.S. Healthcare ETF concentrates on…
1 month ago fool.com
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH
The Invesco Nasdaq Biotechnology ETF carries a lower expense ratio and delivered higher total returns over the trailing 12 months than the iShares U.S. Healthcare ETF. The iShares U.S. Healthcare ETF…
1 month ago benzinga.com
Target, Truist Financial And More On CNBC’s ‘Final Trades’
CNBC’s final trades: Joshua Brown picks Target, Stephanie Link chooses Truist Financial, and Shannon Saccocia recommends iShares U.S. Healthcare ETF.
1 month ago fool.com
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?
iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total…
1 month ago fool.com
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
1 month ago fool.com
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
2 months ago zacks.com
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on June…
2 months ago fool.com
PPH vs. IYH: Which Healthcare Fund Is the Better Buy?
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
2 months ago fool.com
Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.
2 months ago fool.com
IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play?
The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The…
2 months ago benzinga.com
J.B. Hunt Transport, LPL Financial And More On CNBC’s ‘Final Trades’
Experts on CNBC's Halftime Report recommend Roundhill Memory ETF, iShares U.S. Healthcare ETF, and J.B. Hunt Transport.
2 months ago benzinga.com
Justin Wolfers Warns of a 'Pink Collar' Economy Amid July Jobs Report: 'If You Don't Wear Scrubs… You're Losing Jobs'
Economist Justin Wolfers warns of a 'pink collar' economy as the U.S. sheds 23,000 jobs in July, with only the healthcare sector hiring.
3 months ago fool.com
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?
Fidelity MSCI Health Care Index ETF carries a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Fidelity MSCI Health Care Index ETF provides broader…
3 months ago zacks.com
UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch
UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.
3 months ago fool.com
XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield?
State Street Health Care Select Sector SPDR ETF maintains a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Both funds are heavily concentrated in the…
3 months ago fool.com
PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
The iShares U.S. Healthcare ETF (IYH) offers a broader portfolio with a lower expense ratio than the Invesco Pharmaceuticals ETF (PJP). PJP has delivered significantly higher total returns over the…
3 months ago benzinga.com
Apple, Micron, Rocket Companies And More On CNBC’s ‘Final Trades’
Lebenthal picks Micron, Ethridge chooses Rocket Companies, Saccocia recommends iShares U.S. Healthcare ETF, and Brown selects Apple on CNBC's Halftime Report
3 months ago benzinga.com
UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses
UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.
3 months ago fool.com
Which is the Better Choice for Healthcare Investors? IYH or BBH?
iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries…
5 months ago benzinga.com
White House Reportedly Preparing To Oust FDA Commissioner Marty Makary
Trump considers Kyle Diamantas for acting FDA chief as Marty Makary faces potential removal. Stay updated on the leadership transition.
7 months ago benzinga.com
Okta, Phillips 66 And More: CNBC's 'Final Trades'
Okta shares rose 3% to close at $80.76 on Thursday while Phillips 66 shares gained 3.2% to settle at $178.34.
7 months ago benzinga.com
AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss
AbbVie shares fall after early trial data for its obesity drug show up to 9.79% weight loss with generally mild side effects.
8 months ago benzinga.com
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
FDA approves AbbVie's all-oral leukemia treatment combo, showing better three-year outcomes and offering patients a chance for time off therapy compared to standard chemo.
9 months ago benzinga.com
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors recommended staying long on AbbVie.
9 months ago benzinga.com
Alibaba, IBM, Nu Holdings And More: CNBC's 'Final Trades'
Analysts predict good earnings for IBM on Jan. 28. Alibaba forms nuclear power partnership for AI, while iShares and Nu are expected to do well.
11 months ago benzinga.com
Monster Beverage, UnitedHealth, Thermo Fisher Scientific And More: CNBC's 'Final Trades'
Today's "Final Trades" segment focused on UnitedHealth, Thermo Fisher Scientific, iShares U.S. Healthcare ETF and Monster Beverage.
1 year ago benzinga.com
Why Is Co-Diagnostics Stock Sinking Tuesday?
Co-Diagnostics (CODX) stock falls over 50% as they announced a $7 million offering and Saudi joint venture, causing concerns about dilution.
1 year ago benzinga.com
Wellgistics And DataVault Team Up To Transform Prescription Tracking
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.
1 year ago benzinga.com
Premier Set For Private Ownership, Eyes Growth Push
Premier Inc. to be acquired by Patient Square Capital at $28.25 per share, offering shareholders a 23.8% premium.
1 year ago benzinga.com
Brace For Higher Healthcare Premiums In 2026 As Insurers Blame Trump's Tariffs In Filings To Regulators: Report
Health insurance companies have raised concerns that tariffs could lead to higher premiums for enrollees in the individual and small group markets next year.
1 year ago benzinga.com
Guardian Pharmacy Strengthens US Footprint With New Seattle-Area Acquisition
Guardian Pharmacy Services acquires Mercury Pharmacy Services in Washington, expanding its presence in the Pacific Northwest and meeting growing demand for LTC support.
1 year ago benzinga.com
Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines
Year to date, Thermo Fisher fell about 21.03%, both underperforming the iShares U.S. Healthcare ETF, which declined about 2.36%.
1 year ago benzinga.com
Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher.
1 year ago benzinga.com
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
1 year ago benzinga.com
Spotify, Vertiv Holdings And More: CNBC's 'Final Trades'
Joseph M. Terranova picked Spotify Technology, which reported better-than-expected fiscal fourth-quarter 2024 financial sales.
1 year ago benzinga.com
US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21.
1 year ago benzinga.com
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.
1 year ago benzinga.com
World Health Organization Responds to Trump's Order, Reminds Decades of Successful Health Achievements
Trump signs an order to withdraw the U.S. from WHO, citing pandemic mismanagement, political influence, and inequitable funding, reigniting a past debate.
-
1 year ago benzinga.com
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
-
1 year ago benzinga.com
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.
-
2 years ago benzinga.com
Healthcare Investors Bet On Easier Medicare Rules Under Potential Trump Administration
Investors expect Trump to ease Medicare Advantage regulations if he wins another term. This could lead to renewed merger talks among health insurers.
-
2 years ago benzinga.com
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
-
3 years ago benzinga.com
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.